Prasugrel Monotherapy Compared to 12-Month Dual Antiplatelet Therapy in Patients with ST-Elevation Myocardial Infarction Using Platinum-Chromium Everolimus Eluting Stent

What this Trial Is About

Researchers are evaluating the safety of prasugrel monotherapy without aspirin compared to 12-month dual antiplatelet therapy DAPT in patients with ST-segment Elevation Myocardial Infarction STEMI treated with a platinum-chrome everolimus-eluting stent PtCr-EES, SYNERGYTM. The study aims to determine if prasugrel alone is not worse than standard DAPT in preventing major cardiovascular events within 12 months after primary percutaneous coronary intervention PCI. Participants will be assigned to one of two groups one receiving prasugrel monotherapy starting before PCI, and the other receiving both prasugrel and aspirin as dual therapy for 12 months before PCI. This phase 4 trial compares these two antiplatelet strategies to assess their impact on cardiovascular outcomes and bleeding risks. During the study, participants will be monitored for major adverse cardiovascular events over 12 months. Researchers will assess various outcomes including types of bleeding, death causes, myocardial infarction, stroke, stent thrombosis, and need for additional coronary procedures. Safety and efficacy data will be collected throughout to evaluate the treatments under study, with a total participation period of at least one year.

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction